AbCellera Biologics Inc. Selling, General and Administrative Expense
AbCellera Biologics Inc. (ABCL) reported Selling, General and Administrative Expense of $13.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-05
- AbCellera Biologics Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $13.85M, a 37.01% decline year-over-year.
- AbCellera Biologics Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $12.33M, a 35.32% decline year-over-year.
- AbCellera Biologics Inc. selling, general and administrative expense for the quarter ending 2025-06-30 was $21.99M.
- AbCellera Biologics Inc. selling, general and administrative expense for the quarter ending 2025-03-31 was $19.07M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month |
|---|---|---|
| 2026-06-30 | $13.85M 10-Q · filed 2026-08-05 | $26.18M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $12.33M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $21.99M 10-Q · filed 2026-08-05 | $41.05M 10-Q · filed 2026-08-05 |
| 2025-03-31 | $19.07M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |